Clinical trial · Interventional
Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer
NCT03334591CI-TRIAL-00030354unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators hope that after this research, two different treatment methods' curative effects for advanced gastric cancer can be assessed. One is continuous use of apatinib, the other is 5 days' continuous use and 2 days' off of apatinib.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Two Different Treatment Methods | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apatinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Apatinib 5 days' continuous use and 2 days' off
- description
- Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer
- interventionNames
- Drug: Apatinib
- type
- ACTIVE_COMPARATOR
- label
- Apatinib 500mg continuous use
- description
- Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer
- interventionNames
- Drug: Apatinib
Primary outcomes (1)
- measure
- progress free survival(PFS)
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male and female patients,age≥18years 2. Confirmed by Pathology or histology of Gastric cancer 3. Patients who failed first-line chemotherapy 4. The ECOG physical status score:0 to 2 5. Expected survival ≥3months 6. Patients should be voluntary to the trail and provide with signed informed consent. 7. The researchers believe patients can benefit from the study. Exclusion Criteria: 1. Pregnant or lactating women 2. Patients with a knowm history of allergic reactions and/ou hypersensitivity attributed to apatinib or its accessories 3. Patients with apatinib contraindications 4. Patients of doctors considered unsuitable for the trail
References
Publications (1)
- DERIVEDYan Y, Li H, Wu S, Wang G, Luo H, Niu J, Cao L, Hu X, Xu H, Jia W, Sun Y, Yao Y, Chen W, Ke L, Hu B, Ji C, Sun Y, Chen J, Li M, He Y. Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study. Ann Transl Med. 2022 Feb;10(4):205. doi: 10.21037/atm-22-546. PMID 35280426